Roberto Ferrara/X
Sep 8, 2025, 08:51
Roberto Ferrara: Tailoring Combination Treatments to ICI Resistance and Biomarkers
Roberto Ferrara, Medical Oncology Researcher at Vita-Salute San Raffaele University, shared on X:
“We should tailor treatments combined to ICI not only according to markers for new drugs but also according to markers of primary/acquired resistance to ICI.
In patients with PR to chemo-ICI, the worse OS with PARPi suggests a detrimental effect of PARPi on acquired resistance to ICI.”
More Posts Featuring Roberto Ferrara.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 8, 2025, 08:22
Sep 8, 2025, 08:21
Sep 8, 2025, 08:19
Sep 8, 2025, 08:15
Sep 8, 2025, 08:13
Sep 8, 2025, 08:02
Sep 8, 2025, 07:51